Blair William & CO Revance Therapeutics, Inc. Transaction History

Blair William & CO

$31.4 Billion
Q1 2024

A detailed history of Blair William & CO transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Blair William & CO holds 329,267 shares of RVNC stock, worth $846,216. This represents 0.01% of its overall portfolio holdings.

Number of Shares

329,267

Previous 292,949 12.4%

Holding current value

$846,216

Previous $2.58 Million 37.13%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$4.65 - $9.31 $168,878 - $338,120	36,318 Added 12.4%	329,267 $1.62 Million
Q4 2023 Feb 12, 2024	SELL	$5.81 - $11.2 $193,804 - $373,598	-33,357 Reduced 10.22%	292,949 $2.58 Million
Q3 2023 Nov 09, 2023	SELL	$11.47 - $25.07 $1.95 Million - $4.26 Million	-169,969 Reduced 34.25%	326,306 $3.74 Million
Q2 2023 Aug 11, 2023	BUY	$24.7 - $37.61 $4.68 Million - $7.12 Million	189,398 Added 61.72%	496,275 $12.6 Million
Q1 2023 May 12, 2023	BUY	$18.36 - $35.27 $3.33 Million - $6.4 Million	181,372 Added 144.51%	306,877 $9.88 Million

Q4 2022 Feb 10, 2023	BUY	$18.32 - $30.66 $278,464 - $466,032	15,200 Added 13.78%	125,505 $2.32 Million
Q3 2022 Nov 09, 2022	BUY	$14.33 - $28.47 $1.38 Million - $2.74 Million	96,112 Added 677.18%	110,305 $2.98 Million
Q2 2022 Aug 10, 2022	BUY	$11.52 - $20.4 $17,763 - $31,456	1,542 Added 12.19%	14,193 $196,000
Q1 2022 May 13, 2022	SELL	$12.36 - $20.31 $3,708 - $6,093	-300 Reduced 2.32%	12,651 $247,000
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $1.16 Million - $2.6 Million	-93,280 Reduced 87.81%	12,951 $211,000
Q3 2021 Nov 12, 2021	BUY	$25.78 - $33.21 $917,690 - $1.18 Million	35,597 Added 50.4%	106,231 $2.96 Million
Q2 2021 Aug 12, 2021	BUY	$26.8 - $31.84 $780,416 - $927,180	29,120 Added 70.15%	70,634 $2.09 Million
Q1 2021 May 13, 2021	BUY	$24.03 - $29.97 $505,422 - $630,359	21,033 Added 102.7%	41,514 $1.16 Million
Q4 2020 Feb 09, 2021	BUY	$23.41 - $28.34 $225,672 - $273,197	9,640 Added 88.92%	20,481 $580,000
Q3 2020 Nov 06, 2020	SELL	$23.23 - $34.3 $276,320 - $407,998	-11,895 Reduced 52.32%	10,841 $273,000
Q2 2020 Aug 12, 2020	BUY	$12.6 - $26.55 $50,853 - $107,155	4,036 Added 21.58%	22,736 $555,000
Q1 2020 May 11, 2020	BUY	$12.46 - $27.81 $40,495 - $90,382	3,250 Added 21.04%	18,700 $277,000
Q4 2019 Feb 13, 2020	BUY	$11.66 - $20.15 $180,147 - $311,317	15,450 New	15,450 $251,000
Q2 2018 Aug 13, 2018	SELL	$27.45 - $33.35 $226,462 - $275,137	-8,250 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$29.15 - $37.4 $137,005 - $175,780	-4,700 Reduced 36.29%	8,250 $254,000
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $317,922 - $470,084	12,950	12,950 $463,000

Others Institutions Holding RVNC

# of Institutions

214

Shares Held

83.4M

Call Options Held

656K

Put Options Held

424K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account